CARS2

Across TCGA pan-cancer cohorts, CARS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CARS2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CARS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CARS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.157	0.577	.015	17	view →
LUAD	DFS	Median	All	0.944	0.855	.012	11	view →
CCRCC	DFS	Median	III,IV	0.441	0.767	.016	10	view →
LSCC	DFS	Tertile	III,IV	1.000	0.463	.013	8	view →
GBM	DFS	Tertile	All	0.269	0.447	.010	5	view →
HNSC	OS	Median	All	0.641	0.777	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CARS2–PDAC (DFS)

Open the PDAC breakdown →